Trevi Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Trevi Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($11.80M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($12.30M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($10.34M) | May 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($13.24M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($12.35M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($10.90M) | May 8, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($7.70M) | Nov 6, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($7.15M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($6.40M) | May 7, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($8.27M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($8.05M) | Aug 10, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($7.33M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($7.26M) | Nov 10, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($9.79M) | Aug 11, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($8.37M) | May 12, 2022 |
| Q2 | 2021 | Dec 31, 2020 | ($32.80M) | Aug 12, 2021 |
| Q3 | 2021 | Dec 31, 2020 | ($32.80M) | Nov 10, 2021 |
| Q1 | 2021 | Dec 31, 2020 | ($32.80M) | May 13, 2021 |
| Q3 | 2021 | Sep 30, 2020 | ($7.38M) | Nov 10, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($7.38M) | Aug 12, 2021 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($13.92M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($13.72M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($11.47M) | May 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($14.09M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($13.29M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($11.91M) | May 8, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($9.05M) | Nov 6, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($8.38M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($7.56M) | May 7, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($8.41M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($7.82M) | Aug 10, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($7.03M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($6.95M) | Nov 10, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($9.17M) | Aug 11, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($8.09M) | May 12, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($7.24M) | Nov 10, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($7.41M) | Aug 12, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($8.64M) | May 13, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($7.65M) | Nov 12, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($7.42M) | Aug 13, 2020 |